Have a personal or library account? Click to login
Prevalence of Physiological, Pathological and Behavioral Risk Factors in Patients Treated with Antidiabetic Sulfonylureas Cover

Prevalence of Physiological, Pathological and Behavioral Risk Factors in Patients Treated with Antidiabetic Sulfonylureas

Open Access
|Jan 2016

References

  1. 1. Guariguata L, Whiting DR, Hambleton I et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diab Res Clin Pract. 2014;103(2):137-149.10.1016/j.diabres.2013.11.00224630390
  2. 2. Sonia TA, Sharma CP. Oral Delivery of Insulin. Woodhead Publishing. 2014. 1-57.10.1533/9781908818683.1
  3. 3. Virally M, Blickle JF, Girard J, Halimi S, Simon D, Guillausseau PJ. Type 2 diabetes melliuts: epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diab Metab. 2007;33:231-244.10.1016/j.diabet.2007.07.00117703979
  4. 4. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metab Clin Experim. 2006;55(Suppl 1): S20-S27.10.1016/j.metabol.2006.02.00316631807
  5. 5. Germino FW. Noninsulin Treatment of Type 2 Diabetes mellitus in Geriatric Pacients: A review. Clin Therap. 2011; 33(12):1868-1882.10.1016/j.clinthera.2011.10.02022136979
  6. 6. Solet JL, Baroux N, Pochet M, et al. Prevalence of type 2 diabetes and other cardiovascular risk factors in Mayotte in 2008: The Maydia study, Diabetes & Metabolism. 2011;37:201-207.
  7. 7. Foster DW. Diabetul zaharat. In: Harrison – Principiile medicinei interne. Bucharest, Romania: Teora, 2003. 2265-2294.
  8. 8. Belhatem N, Mohammedi K, Rouzet F, et al. Impact of morbid obesity on the kidney function of patientis with type 2 diabetes. Diabetes Res and Clin Pract. 2015;108(1):143-149.10.1016/j.diabres.2015.01.02825666105
  9. 9. Fukui M, Tanaka M, Toda H, et al. Risk factors for the developement of diabetes mellitus, hypertension and dyslipidemia. Diabetes Res and Clin Pract. 2011,94(1):15-18.10.1016/j.diabres.2011.07.00621802759
  10. 10. Samaranayaka S, Gulliford MC. Trends in cardiovascular risk factors among people with diabetes in a population based study, Health survey for England 1994-2009. Primary Care Diabetes. 2013;7(3):193-198.10.1016/j.pcd.2013.04.01023685024
  11. 11. Taskinen MR, Borén J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis. 2015;239(2): 483-495.10.1016/j.atherosclerosis.2015.01.03925706066
  12. 12. Lastra G, Syed S, Kurukulasuriya LR et al., Type 2 Diabetes Mellitus and Hypertension: An Update. Endocrinology and Metabolism Clinics of North America. 2014;43(1):103-122.10.1016/j.ecl.2013.09.005394266224582094
  13. 13. Frontoni S, Solini A, Fioretto P, et al. The ideal blood pressure target to prevent cardiovascular disease in type 2 diabetes: A neutral viewpoint. Nutrition, Metabolism and Cardiovascular Diseases. 2014;24(6):577-584.10.1016/j.numecd.2014.01.00424582686
  14. 14. Wei X, Meng E, Sufang Yu. A meta-analysis of passive smoking and risk of developing type 2 diabetes mellitus. Diabetes Res and Clin Pract. 2015;107(1):9-14.10.1016/j.diabres.2014.09.01925488377
DOI: https://doi.org/10.1515/amma-2015-0080 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755
Language: English
Page range: 342 - 344
Submitted on: Jun 4, 2015
|
Accepted on: Aug 5, 2015
|
Published on: Jan 19, 2016
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year

© 2016 Confederat Luminita, Stefan Roxana, Constantin Sandra, Hăncianu Monica, Profire Lenuta, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.